EU Non-Alcoholic Steatohepatitis (NASH) Market, by Type (Serum Biomarker, Hepatic Fibrosis Biomarker, Apoptosis Biomarker, Oxidative Stress Biomarker, Other Types) by End-User (Pharma & Cro Industry, Diagnostic lab, Academic Research Key, Hospital) Growth, Trends and Forecast, 2019-2028
- Published Date: 2022-12-26
- Report ID: 138180
- Pages: 200
-
Format:
Report Overview
The EU Non-alcoholic Steatohepatitis (Nash)market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 19.55% during the forecast period
NASH is a form of NAFLD in which you have hepatitisinflammation of the liverand liver cell damage, in addition to fat in your liver. Inflammation and liver cell damage can cause fibrosis, or scarring, of the liver. NASH may lead to cirrhosis or liver cancer link
Market Drivers
In the United Kingdom, the NASH cases are set to reach 3.9 million by 2030, as per the 2018 EMA Workshop on Liver Diseases data. Also, the NHS data suggests that one in every three people suffer from NAFLD. Liver disease results in death for more than 40 people every day in the UK. Obesity has also become a significant health concern, according to the OECD data. It is evaluated that one in every four adults is impacted by obesity. Clinical trials for NAFLD is second-highest in the UK, after the US. Such factors are expected to boost the market growth in the UK
1. EU Non-alcoholic Steatohepatitis (Nash) Market Overview
A. Market Size
2. EU Non-alcoholic Steatohepatitis (Nash) Market Growth Drivers
I. Growing Nash Affected Population
II. Surging Prevalence of Obesity and Diabetes
III. Increasing occurrence of Chronic Disease
IV. Surging Awareness of Non-Alcoholic Fatty Liver Disease
3. EU Non-alcoholic Steatohepatitis (Nash) Market Segmentation.
A. By Type
I. Serum Biomarker
II. Hepatic Fibrosis Biomarker
III. Apoptosis Biomarker
IV. Oxidative Stress Biomarker
V. Other types
B. By End-User
I. Pharma & Cro Industry
II. Diagnostic Lab
III. Academic Research Key
IV. Hospital
4. EU Non-alcoholic Steatohepatitis (Nash) Market Major Market Share
A. Market Analysis, Insights and Forecast by Revenue
5. Competitive Landscape
A. Major Players
B. Products in Pipeline
6. Key Company Profiles..
A. Janssen Company overview, Product & Services, Strategies & Financials
B. Astra Zeneca Company overview, Product & Services, Strategies & Financials
C. Eli Lilly Company overview, Product & Services, Strategies & Financials
7. Healthcare Policies and Regulatory Landscape.
A. Policy Changes and Reimbursement Scenario
8. Factors Driving Market Growth
A. Key Industry Developments
B. Mergers and Acquisitions
9. Market Opportunities and Future Trends
A. Market Opportunities
B. Future Trends
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
